Abstract
In 2022, one novel pharmaceutical agent was released on the German market for horses or food-producing animals: An injection suspension for horses containing tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells as the active ingredient (RenuTend®) is now available. The authorization of one established veterinary active ingredient was extended to an additional species: The synthetic prostaglandin F2α-analogue cloprostenol (Syncroprost®) received approval for goats. Additionally, for 2 active ingredients (paracetamol, suxibuzone), drugs with a higher content of the active ingredient were launched on the market for horses and food-producing animals.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
